[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral Vectors, and Non-Viral Vectors) and Application (Cancers, Inherited Disorders, Viral Infections and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027

September 2020 | 188 pages | ID: V9E88F1CA6CEN
Allied Market Research

US$ 5,769.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The global viral vectors and plasmid DNA manufacturing market was valued at $918.37 million in 2019, and is estimated to reach at $4,978.54 million by 2027, registering a CAGR of 24.9% from 2020 to 2027. Gene therapies require a viral or non-viral vector to efficiently transfer therapeutic gene into target cells.

Manufacturing of viral vectors and plasmid DNA is based on a unique concept, which states that two people infected with same disease do not have same physical response toward the disease. However, it depends on the surrounding environment and influence of genes and symptoms of a patient. Moreover, it depends on a patient’s ability to respond to a particular disease, which enables doctors and researchers to organize the required treatment. Viral vectors and plasmid DNA manufacturing generally includes use of system biology and panomics to determine the cause of a patient's illness at the molecular level, followed by the use of concentrated medications to address individual patient's illness. Furthermore, viral vectors and plasmid DNA can reduce the cost of treatment and help decrease repeated administration of medications.

The global viral vectors and plasmid DNA manufacturing market is segmented on the basis of product, application, and region On the basis of product, it is divided into plasmid DNA, viral vectors, and non-viral vectors. By application, it is categorized into cancer, inherited disorders, viral infections, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The global viral vectors and plasmid DNA manufacturing market is expected to grow at a productive rate during the forecast period.

Surge in global incidences of cancer and increase in ageing population susceptible to diseases are expected to boost the demand for viral vectors and plasmid DNA manufacturing. However, high cost associated with gene therapies and risk of mutagenesis & other impediments in gene therapy restrain the market growth. Moreover, government initiatives & grants and surge in investments by private companies on R&D of viral vectors and plasmid DNA manufacturing are expected to boost the market growth.

KEY BENEFITS FOR STAKEHOLDERS
          • This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify prevailing opportunities along with strategic assessment of the global viral vectors and plasmid DNA manufacturing market.
  • Market size and estimations are based on a comprehensive analysis of end users, developments, and services in the industry.
      • An in-depth analysis based on region assists to understand the regional market and facilitates strategic business planning.
          • Developmental strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS

By Product
  • Plasmid DNA
  • Viral Vectors
  • Non-viral Vectors
By Application
  • Cancers
  • Inherited Disorders
  • Viral Infections
  • Others
By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
KEY MARKET PLAYERS
  • COGNATE BIOSERVICES, INC.
  • CATALENT PHARMA SOLUTIONS
  • F. HOFFMANN-LA ROCHE LTD
  • FUJIFILM HOLDINGS CORPORATION
  • JOHNSON & JOHNSON
  • 4D MOLECULAR THERAPEUTICS
  • SANOFI CORPORATION
  • SIRION BIOTECH GMBH
  • VOYAGER THERAPEUTICS
  • THERMO FISHER SCIENTIFIC
OTHER MARKET PLAYERS
  • CELL AND GENE THERAPY CATAPULT
  • UNIQURE
  • MASSBIOLOGICS
  • RENOVA THERAPEUTICS
  • SHENZHEN SIBIONO GENETECH CO., LTD
CHAPTER 1: INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
  1.4.1.Secondary research
  1.4.2.Primary research
  1.4.3.Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
  3.2.1.Top investment pockets
  3.2.2.Top winning strategies
  3.2.3.Top player positioning, 2019
3.3.Porter’s five force analysis
3.4.Market dynamics
  3.4.1.Drivers
    3.4.1.1.Increase in funding for R&D activities pertaining to gene therapy
    3.4.1.2.Rise in prevalence of cancer, viral infections, and genetic disorders
    3.4.1.3.Increase in awareness regarding gene therapies
  3.4.2.Restraints
    3.4.2.1.High cost associated with gene therapies
    3.4.2.2.Risk of mutagenesis and other impediments in gene therapy
  3.4.3.Opportunities
    3.4.3.1.Increase in demand for synthetic genes
    3.4.3.2.Untapped markets in developing economies
3.5.COVID-19 Impact Analysis for Viral Vector and Plasmid DNA Manufacturing Market

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT

4.1.Overview
  4.1.1.Market size and forecast
4.2.Viral vectors
  4.2.1.Key market trends, growth factors, and opportunities
  4.2.2.Market size and forecast, by region
  4.2.3.Market analysis, by country
4.3.Plasmid DNA
  4.3.1.Key market trends, growth factors, and opportunities
  4.3.2.Market size and forecast, by region
  4.3.3.Market analysis, by country
4.4.Non-viral vectors
  4.4.1.Key market trends, growth factors, and opportunities
  4.4.2.Market size and forecast, by region
  4.4.3.Market analysis, by country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

5.1.Overview
  5.1.1.Market size and forecast
5.2.Cancer
  5.2.1.Market size and forecast, by region
  5.2.2.Market analysis, by country
5.3.Inherited disorder
  5.3.1.Market size and forecast, by region
  5.3.2.Market analysis, by country
5.4.Viral Infection
  5.4.1.Market opportunities associated with COVID 19 Pandemic
  5.4.2.Market size and forecast, by region
  5.4.3.Market analysis, by country
5.5.Others
  5.5.1.Market size and forecast, by region
  5.5.2.Market analysis, by country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

6.1.Overview
  6.1.1.Market size and forecast
6.2.North America
  6.2.1.Key market trends, growth factors, and opportunities
  6.2.2.North America viral vectors and plasmid DNA manufacturing market , by country
    6.2.2.1.U.S. viral vectors and plasmid DNA manufacturing market, by product
    6.2.2.2.U.S. viral vectors and plasmid DNA manufacturing market, by application
    6.2.2.3.Canada viral vectors and plasmid DNA manufacturing market, by product
    6.2.2.4.Canada viral vectors and plasmid DNA manufacturing market, by application
    6.2.2.5.Mexico viral vectors and plasmid DNA manufacturing market, by product
    6.2.2.6.Mexico viral vectors and plasmid DNA manufacturing market, by application
  6.2.3.North America viral vectors and plasmid DNA manufacturing, by product
  6.2.4.North America viral vectors and plasmid DNA manufacturing, by application
6.3.Europe
  6.3.1.Key market trends, growth factors, and opportunities
  6.3.2.Europe viral vectors and plasmid DNA manufacturing, by country
    6.3.2.1.UK viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.2.UK viral vectors and plasmid DNA manufacturing market, by application
    6.3.2.3.Germany viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.4.Germany viral vectors and plasmid DNA manufacturing market, by application
    6.3.2.5.France viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.6.France viral vectors and plasmid DNA manufacturing market, by application
    6.3.2.7.Italy viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.8.Italy viral vectors and plasmid DNA manufacturing market, by application
    6.3.2.9.Spain viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.10.Spain viral vectors and plasmid DNA manufacturing market, by application
    6.3.2.11.Rest of Europe viral vectors and plasmid DNA manufacturing market, by product
    6.3.2.12.Rest of Europe viral vectors and plasmid DNA manufacturing market, by application
  6.3.3.Europe viral vectors and plasmid DNA manufacturing, by product
  6.3.4.Europe viral vectors and plasmid DNA manufacturing, by application
6.4.Asia Pacific
  6.4.1.Key market trends, growth factors, and opportunities
  6.4.2.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by country
    6.4.2.1.Japan viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.2.Japan viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.3.China viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.4.China viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.5.Australia viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.6.Australia viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.7.India viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.8.India viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.9.South Korea viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.10.South Korea viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.11.Taiwan viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.12.Taiwan viral vectors and plasmid DNA manufacturing market, by application
    6.4.2.13.Rest of Asia-Pacific viral vectors and plasmid DNA manufacturing market, by product
    6.4.2.14.Rest of Asia-Pacific viral vectors and plasmid DNA manufacturing market, by application
  6.4.3.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by product
  6.4.4.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by application
6.5.LAMEA
  6.5.1.Key market trends, growth factors, and opportunities
  6.5.2.LAMEA viral vectors and plasmid DNA manufacturing market, by country
    6.5.2.1.Brazil viral vectors and plasmid DNA manufacturing market, by product
    6.5.2.2.Brazil viral vectors and plasmid DNA manufacturing market, by application
    6.5.2.3.Saudi Arabia viral vectors and plasmid DNA manufacturing market, by product
    6.5.2.4.Saudi Arabia viral vectors and plasmid DNA manufacturing market, by application
    6.5.2.5.South Africa viral vectors and plasmid DNA manufacturing market, by product
    6.5.2.6.South Africa viral vectors and plasmid DNA manufacturing market, by application
    6.5.2.7.Rest of LAMEA viral vectors and plasmid DNA manufacturing market, by product
    6.5.2.8.Rest of LAMEA viral vectors and plasmid DNA manufacturing market, by application
  6.5.3.LAMEA viral vectors and plasmid DNA manufacturing market, by product
  6.5.4.LAMEA viral vectors and plasmid DNA manufacturing market, by application

CHAPTER 7: COMPANY PROFILES

7.1.COGNATE BIOSERVICES, INC.
  7.1.1.Company overview
  7.1.2.Company snapshot
  7.1.3.Operating business segment
  7.1.4.Product portfolio
  7.1.5.Key strategic moves and developments
7.2.CATALENT PHARMA SOLUTIONS
  7.2.1.Company overview
  7.2.2.Company snapshot
  7.2.3.Operating business segment
  7.2.4.Product portfolio
  7.2.5.Business performance
  7.2.6.Key strategic moves and developments
7.3.FUJIFILM HOLDINGS CORPORATION
  7.3.1.Company overview
  7.3.2.Company snapshot
  7.3.3.Operating business segment
  7.3.4.Product portfolio
  7.3.5.Business performance
  7.3.6.Key strategic moves and developments
7.4.JOHNSON & JOHNSON
  7.4.1.Company overview
  7.4.2.Company snapshot
  7.4.3.Operating business segment
  7.4.4.Product portfolio
  7.4.5.Business performance
  7.4.6.Key strategic moves and developments
7.5.F. HOFFMANN-LA ROCHE LTD.
  7.5.1.Company overview
  7.5.2.Company snapshot
  7.5.3.Operating business segment
  7.5.4.Product portfolio
  7.5.5.Business performance
  7.5.6.Key strategic moves and developments
  7.6.4D MOLECULAR THERAPEUTICS
  7.6.1.Company overview
  7.6.2.Company snapshot
  7.6.3.Operating business segment
  7.6.4.Product portfolio
  7.6.5.Key strategic moves and developments
7.7.SANOFI CORPORATION
  7.7.1.Company overview
  7.7.2.Company snapshot
  7.7.3.Operating business segment
  7.7.4.Product portfolio
  7.7.5.Business performance
7.8.SIRION BIOTECH GmbH
  7.8.1.Company overview
  7.8.2.Company snapshot
  7.8.3.Operating business segment
  7.8.4.Product portfolio
7.9.THERMO FISHER SCIENTIFIC, INC.
  7.9.1.Company overview
  7.9.2.Company snapshot
  7.9.3.Operating business segment
  7.9.4.Product portfolio
  7.9.5.Business performance
  7.9.6.Key strategic moves and developments
7.10.VOYAGER THERAPEUTICS INC.
  7.10.1.Company overview
  7.10.2.Company snapshot
  7.10.3.Operating business segment
  7.10.4.Product portfolio
  7.10.5.Business performance
  7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PLASMID DNAS, BY REGION, 2019–2027 ($MILLION)
TABLE 04.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY NON-VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
TABLE 05.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 06.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY CANCER, BY REGION, 2019–2027 ($MILLION)
TABLE 07.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY INHERITED DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 09.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 11.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 13.U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 14.CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 15.CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 17.MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 20.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 22.UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 23.GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 24.GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 25.FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 26.FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 27.ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 28.ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 29.SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 30.SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 31.REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 32.REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 33.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 35.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 36.JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 37.JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 38.CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 39.CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 40.AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 41.AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 42.INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 43.INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 44.SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 46.TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 47.TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 50.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 52.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 53.BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 54.BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 55.SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 56.SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 58.SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 59.REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 60.REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 63.COGNATE: COMPANY SNAPSHOT
TABLE 64.COGNATE: OERATING SEGMENT
TABLE 65.COGNATE: PRODUCT PORTFOLIO
TABLE 66.COGNATE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 67.CATALENT: COMPANY SNAPSHOT
TABLE 68.CATALENT: OPERATING SEGMENTS
TABLE 69.CATALENT: PRODUCT PORTFOLIO
TABLE 70.CATALENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 71.FUJIFILM: COMPANY SNAPSHOT
TABLE 72.FUJIFILM: OPERATING BUSINESS SEGMENT
TABLE 73.FUJIFILM: PRODUCT PORTFOLIO
TABLE 74.J&J: COMPANY SNAPSHOT
TABLE 75.J&J: OPERATING BUSINESS SEGMENT
TABLE 76.J&J: PRODUCT PORTFOLIO
TABLE 77.ROCHE: COMPANY SNAPSHOT
TABLE 78.ROCHE: OPERATING SEGMENTS
TABLE 79.ROCHE: PRODUCT PORTFOLIO
TABLE 80.4D: COMPANY SNAPSHOT
TABLE 81.4D: OPERATING SEGMENTS
TABLE 82.4D: PRODUCT PORTFOLIO
TABLE 83.SANOFI: COMPANY SNAPSHOT
TABLE 84.SANOFI: OPERATING SEGMENTS
TABLE 85.SANOFI: PRODUCT PORTFOLIO
TABLE 86.SIRION: COMPANY SNAPSHOT
TABLE 87.SIRION: OPERATING SEGMENTS
TABLE 88.SIRION: PRODUCT PORTFOLIO
TABLE 89.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 90.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
TABLE 91.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 92.VOYAGER: COMPANY SNAPSHOT
TABLE 93.VOYAGER: PRODUCT PORTFOLIO
TABLE 94.VOYAGER: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF SUBSTITUTES
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.DRIVER, RESTRAINSTS AND OPPORTUNITIES
FIGURE 13.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PLASMID DNAS, BY REGION, 2019–2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY NON-VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY CANCERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY INHERITED DISORDERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL INFECTION, BY REGION, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 20.CATALENT: NET SALES, 2017–2019 ($MILLION)
FIGURE 21.CATALENT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22.CATALENT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23.FUJIFILM: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 25.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 26.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 27.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 28.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 30.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 33.SANOFI: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 34.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 36.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 37.VOYAGER: NET SALES, 2017–2019 ($MILLION)


More Publications